ArticleScience translational medicine2023
RNF41 orchestrates macrophage-driven fibrosis resolution and hepatic regeneration.
Article in Science translational medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 34 citations in OpenAlex.
- Targeting the E3 ubiquitin ligase RNF10 ameliorates metabolic dysfunction-associated steatohepatitis in mice.The Journal of clinical investigation · 2026Article
- Macrophage heterogeneity in organ fibrosis in the era of single-cell omics.Molecular biology reports · 2026Review
- Reprogramming macrophages to treat liver diseases.Hepatology (Baltimore, Md.) · 2026Review
- Integrated transcriptomic analysis identifies liver aging-driven fibrosis signatures and reveals therapeutic strategies based on medicine-food homology.NPJ science of food · 2026Article
- Sertoli Cell-Derived Extracellular Vesicles Orchestrate Cadmium-Induced Testicular Inflammation and Fibrosis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- TRIM13 in situ engineering boosts anti-inflammatory capacity of CAR-Ms for liver fibrosis therapy.Nature communications · 2026Article
- Strategies to promote liver fibrosis amelioration with involvement of restorative macrophages.Frontiers in immunology · 2026Review
- 3D endothelial cell scaffolds protect liver explants and exhibit therapeutic effects on liver fibrosis.JHEP reports : innovation in hepatology · 2026Article
- Emerging nanomedicine for liver diseases treatment.Journal of nanobiotechnology · 2025Review
- Antifibrotic therapies for metabolic dysfunction-associated steatotic liver disease.JHEP reports : innovation in hepatology · 2025Review
- Branched Polymer Architecture for Modulating Interactions in Material-Bio Interface.Tissue engineering and regenerative medicine · 2025Review
- Liver diseases: epidemiology, causes, trends and predictions.Signal transduction and targeted therapy · 2025Review
- Engineered Mesenchymal Stem Cell-Derived Small Extracellular Vesicles Mitigate Liver Fibrosis by Delivering USP10 to Reprogram Macrophage Phenotype.Biomaterials research · 2025Article
- Hypermethylation of Ring finger protein 41 promoter is associated with early hepatitis B virus-related cirrhosis.Frontiers in medicine · 2025Article
- Nanoparticle technologies for liver targeting and their applications in liver diseases.Frontiers in bioengineering and biotechnology · 2025Review
- Advances in the understanding of the role and mechanism of action of PFKFB3‑mediated glycolysis in liver fibrosis (Review).International journal of molecular medicine · 2024Review
- Review
- Liver macrophages revisited: The expanding universe of versatile responses in a spatiotemporal context.Hepatology communications · 2024Review
- Disruption of TIGAR-TAK1 alleviates immunopathology in a murine model of sepsis.Nature communications · 2024Article
- USP8 prevents aberrant NF-κB and Nrf2 activation by counteracting ubiquitin signals from endosomes.The Journal of cell biology · 2024Article
Corrections and comments
- Commented on by
Authors and funding
11 authors at 5 institutions in 2 countries.
Funding
Abstract
Hepatic inflammation is a common trigger of chronic liver disease. Macrophage activation is a predictive parameter for survival in patients with cirrhosis. Ring finger protein 41 (RNF41) negatively regulates proinflammatory cytokines and receptors; however, the precise involvement of macrophage RNF41 in liver cirrhosis remains unknown. Here, we sought to understand how RNF41 dictates macrophage fate in hepatic fibrosis and repair within the inflammatory milieu. We found that
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.